AB017. Increased dendritic cells and IFN-beta and MxA protein expression in spongiotic dermatitis differentiates dermatomyositis from eczema

Abstract

BackgroundDermatomyositis (DM) is conventionally characterized by interface dermatitis (ID) on skin histopathology. A subset of patients with clinically diagnosed DM have skin biopsies showing spongiotic dermatitis (SD), a histopathology more commonly seen in eczema. Diagnosis of DM is challenging, with significant delays following initial presentation. (I) To identify the percentage of clinically diagnosed DM patients with skin biopsies showing SD, (II) to identify cytokine and cell markers that can determine if a skin biopsy showing SD is consistent with DM in a patient with clinical DM.MethodsBiopsies from 10 DM patients with SD histopathology were compared to biopsies from 10 healthy controls, 10 patients with eczema, and 12 patients with DM with ID histopathology. Skin biopsies were stained by H&E and by immunohistochemistry for MxA, IFN-beta, CD11c (mDC), and BDCA2 (pDC). Cytokines were quantified by area and intensity. Cells were quantified per HPF. Fisher’s exact test was used to compare baseline patient characteristics. One-way ANOVA with Bonferroni’s multiple comparison test was used to compare protein expression between groups.ResultsEleven of 164 (6.7%) patients with a clinical diagnosis of DM at our tertiary care center were identified as having SD. MxA, IFN-beta, CD11c (mDC), and BDCA2 (pDC) protein expression is significantly higher in DM-SD compared to eczema and healthy controls. Expression of MxA, IFN-beta and BDCA2 were not significantly different between DM-SD and DM-ID.ConclusionsIncreased MxA, IFN-beta, CD11c, and BDCA2 protein expression can help distinguish between DM-SD and eczema.